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Background: Atrial ﬁbrillation (AF) is common in patients with aortic stenosis (AS) although the exact mecha-
nism is unclear. The purpose of this study was to investigate echocardiographic characteristics among patients
with severe AS and AF and to identify factors associated with the development of new-onset AF after aortic
valve replacement (AVR).
Methods:125patientswith severe AS and ejection fraction N40% scheduled for AVRwere evaluatedpreoperative-
ly and 3, 6, 9 and 12 months postoperatively with electrocardiography (ECG) and echocardiography, and Holter-
ECG analysis was performed after 3 and 12 months. The primary endpoint was new-onset AF deﬁned as an
episode of AF exceeding 30 s, on the ECG or Holter-ECG and/or patients hospitalized due to AF.
Results: AF was present in 19 patients prior to AVR, compared to patients in sinus rhythm AF patients had
increased NT-proBNP, increased left atrial (LA) volume (61 ± 21 vs. 47 ± 17ml/m2, p = 0.002), reduced global
longitudinal left ventricular strain (−13.1 ± 3.7 vs.−16.0 ± 3.5, p = 0.002) and presented more often with a
restrictive ﬁlling pattern (37% vs. 10%, p = 0.002). During follow-up 23 patients developed new-onset AF;
predictors were LA volume, restrictive ﬁlling pattern, NT-proBNP, E/e′ and systolic blood pressure. After
correcting for age and LA volume index, a restrictive ﬁlling pattern and systolic blood pressure remained
associated with new-onset AF.
Conclusions: The presence of preoperative AF and development of new-onset AF after AVR is associated with
restrictive ﬁlling pattern and LA dilatation in patients with severe AS.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Atrial ﬁbrillation (AF) is the most common sustained cardiac
arrhythmia affecting up to 1.5–2% of the general population [1] and
more than 9% in patients with aortic stenosis (AS) [2] and is indepen-
dently associated with increased mortality and serious cardiovascular
events such as ischemic stroke, systemic thromboembolism, and heart
failure [3].
AS is a progressive disease involving lipid accumulation, extracellu-
larmatrix deposition and inﬂammatory response of the valve apparatus
leading to chronic left ventricular (LV) and left atrial (LA) pressure over-
load. Due to direct effects on the myocardium, pressure overload leads
to LV hypertrophy and myocardial ﬁbrosis, which increase myocardial
stiffness. The consequences of these pathophysiological processes arewith Identiﬁer: NCT00294775.
dense University Hospital, Sdr.
.
and Ltd. This is an open access articlediastolic dysfunction, increased LV ﬁlling pressures, increased LA
pressure and LA dilatation.
Systemic hypertension (LV pressure overload) especially when
associated with LV hypertrophy are considered predictors of AF [4–6].
The exact pathophysiological mechanisms, however, underlying the
relation between elevated afterload and the development of AF remain
unclear. The association of AS with AF is thus not fully understood. The
aim of this study was to investigate echocardiographic and biomarker
characteristics among patients with severe symptomatic AS and AF
and to evaluate factors able to predict the development of new-onset
AF after aortic valve replacement (AVR).
2. Methods
The present investigation is a sub-study of a prospective single cen-
ter, randomized study to evaluate the effect of candesartan on top of
conventional treatment on reverse remodeling in consecutive patients
undergoing AVR for symptomatic AS. The study was registered with
the National Board of Health and the Danish Data Protection Agencyunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
103J.S. Dahl et al. / IJC Heart & Vessels 4 (2014) 102–107and approved by the local ethics committee. All patients gave written
informed consent. ClinicalTrials.gov Identiﬁer: NCT00294775. The
study design and the results regarding the effect of candesartan on re-
gression of LV hypertrophy have previously been published [7]. In
brief, we enrolled patients aged N18 years with symptomatic severe
AS (estimated aortic valve area b1 cm2) scheduled for AVR at Odense
University Hospital, Denmark between February 2006 and April 2008.
Patientswith LV ejection fraction b40%, s-creatinine N220 μmol/l, previ-
ous aortic valve surgery, planned additional valve repair/replacement,
infective endocarditis, predominant aortic valve regurgitation, or on-
going treatment with an angiotensin converting enzyme inhibitor or
an angiotensin receptor blocker were excluded.
2.1. Echochardiography
All echocardiograms were performed by the same experienced
operator on a GE Vivid 5 ultrasound system (GE Medical System,
Horten, Norway), the day prior to surgery. Echocardiograms were
digitally stored and later analyzed completely blinded for all clinical
and survival data. Aortic valve area was estimated by quantitative
Doppler ultrasound using the continuity equation. Peak ﬂow velocity
across the valve was determined in the window where the highest ve-
locity could be recorded using continuouswaveDopplerwith the cursor
as parallel as possible with the ﬂow across the valve. Peak transvalvular
gradient was estimated using the modiﬁed Bernoulli equation. Finally,
the peak systolic ﬂow velocity in the outﬂow tract was estimated with
pulsed wave Doppler [8].
As ameasure of LVhypertrophy, LVmasswas estimated according to
the joint recommendations of the American (ASE) and European (EAE)
associations of echocardiography using Devereux's formula [9]. Relative
wall thickness was calculated using the formula 2 × posterior wall
thickness / LV internal diameter in diastole [10]. LV ejection fraction
was estimated using Simpson's biplane method. Longitudinal LV systol-
ic function was assessed using peak systolic mitral annular motion
assessed with tissue Doppler imaging with the Doppler sample volume
placed in the septal mitral valve annulus. Global longitudinal strain
(GLS) was analyzed using EchoPAC PC 08 (GE Medical system, Horten,
Norway) speckle tracking software 2-D. GLS was determined as theTable 1
Baseline characteristics of the study population.
Atrial ﬁbrillation prior to AV
n = 19
Age (y) 76 ± 8
Sex (male) 13 (68)
NYHA I/II/III/IV 6/8/5/0
Diabetes mellitus 3 (16)
Ischemic heart disease 1 (5)
EuroScore 6.5 ± 2.0
Aortic valve area (cm2) 0.76 ± 0.29
Aortic valve mean gradient (mmHg) 33 ± 17
Valvulo-arterial impedance (ml/mmHg) 5.3 ± 1.7
Ejection fraction (%) 54 ± 7
Left ventricular end-diastolic volume (ml) 108 ± 39
Left ventricular mass index (g/m2) 144 ± 46
Relative wall thickness 0.63 ± 0.09
Left atrial volume index (ml/m2) 61 ± 21
E-velocity (m/s) 0.96 ± 0.26
Deceleration time (ms) 176 ± 67
Deceleration time b140 ms 7 (37)
e′ (cm/s) 7.2 ± 2.4
s′ (cm/s) 5.1 ± 1.5
E/e′ 14.4 ± 5.8
Global longitudinal strain (%) −13.1 ± 3.7
Systolic strain rate (s−1) −0.75 ± 0.27
Log-NTproBNP 7.2 ± 1.0
Fibulin-1 (μg/ml) 104 ± 34
Abbreviations: NYHA New York Heart Association.magnitude of strain at the aortic valve closure, and systolic strain rate
(SRS) was determined as the maximal negative SR value during the
ejection phase. Both parameters were assessed in all 3 apical planes,
and the mean values (GLSmean, SRsmean) were calculated. Frame rate
was kept as high as possible with a minimum frame rate of 70/s.
Mitral inﬂow was assessed in the apical four-chamber view using
pulsed-wave Doppler with the sample volume placed at the tips of
mitral leaﬂets during diastole. From the mitral inﬂow proﬁle, the E-
and A-wave peak velocities and deceleration time were measured.
Doppler tissue imaging of the mitral annulus, was used in the septal
annulus to measure the early diastolic e′−velocity. The E/e′−ratio
was used as a non-invasive marker of LV ﬁlling pressures [11]. E/e′
greater than 15 was considered consistent with increased ﬁlling
pressure. Diastolic ﬁlling pattern and restrictive ﬁlling pattern was cat-
egorized according to European Association of Echocardiography
(EAE) guidelines [12].
LA volume was assessed using the area length method [9] from the
apical four and two-chamber views. Measurements were obtained in
end-systole from the frame preceding mitral valve opening, and the
volume was indexed for body surface area. Patients were considered
to have severe LA dilatation if left atrial volume index (LAVi) was
40 ml/m2 or greater.
2.2. Assessment of atrial ﬁbrillation
Patients were examined at 3, 6, 9 and 12 months after AVR and
underwent a 12-lead ECG for 2 min in the supine position. In addition,
24-hour Holter monitoring was performed at 3 months and 48-hour
Holter monitoring at 12 months follow-up using a Reynolds Medical
Tracker 3 recorder and the Pathﬁnder 700 analyzer (Reynolds Medical
Limited, U.K.). All ECGs were interpreted by the same experienced
cardiologist blinded for all clinical, echocardiographic and survival
data. An episode of irregular heart rhythm without deﬁnite p-waves
and with a minimum duration of 30 s was considered as AF according
to guidelines [13]. Short episodes of supraventricular tachycardia
(SVT) b30 s were recorded separately. AF episodes occurring within
30 days of valve replacement were regarded as postoperative AF and
not included as an endpoint.R No atrial ﬁbrillation prior to AVR
n = 106
72 ± 9 0.10
66 (62) 0.61
17/57/31/1 0.43
16 (15) 0.94
22 (21) 0.11
5.6 ± 2.0 0.08
0.82 ± 0.27 0.41
37 ± 17 0.42
4.8 ± 1.5 0.28
54 ± 8 0.75
110 ± 33 0.82
128 ± 39 0.13
0.59 ± 0.15 0.31
47 ± 17 0.002
0.77 ± 0.21 0.001
202 ± 57 0.03
11 (10) 0.002
5.4 ± 0.1.3 b0.0001
5.8 ± 1.5 0.04
15.0 ± 5.2 0.69
−16.0 ± 3.5 0.002
−0.85 ± 0.18 0.049
6.1 ± 1.3 0.0002
86 ± 32 0.02
Table 2
Clinical characteristics of patients with new-onset atrial ﬁbrillation (NOAF).
NOAF
n = 23
No NOAF
n = 83
Age (y) 74 ± 8 71 ± 9 0.17
Sex (male) 13 (57) 53 (64) 0.63
Diabetes mellitus 2 (9) 14 (17) 0.33
Ischemic heart disease 8 (35) 14 (17) 0.06
EuroScore 5.7 ± 2.1 5.6 ± 1.9 0.75
Systolic blood pressure (mmHg) 155 ± 23 145 ± 18 0.02
Beta-blocker therapy 5 (22) 18 (22) 1.00
Diuretic therapy 7 (30) 30 (36) 0.61
Calcium channel blockers 3 (13) 19 (23) 0.30
NYHA I/II/III/IV 4/14/4/1 13/43/27/0 0.18
Log-NTproBNP 6.6 ± 1.3 5.9 ± 1.2 0.02
Fibulin-1 (μg/ml) 93 ± 41 84 ± 29 0.25
Atrial ﬁbrillation b 30 s 14 (61) 30 (36) 0.05
Supraventricular tachycardia episodes (median) 0 (0–1) 2 (0–15) 0.03
- N1 episodes 18 (78) 46 (55) 0.04
- N2 episodes 17 (74) 41 (49) 0.04
- N3 episodes 17 (74) 39 (47) 0.02
Abbreviations: NYHA New York Heart Association.
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Blood samples were collected immediately after the echocardio-
gram, when the subjects had been resting recumbent for at least
30 min. Samples were collected in EDTA tubes and then centrifuged.
Plasma samples were stored at−80 °C for later analysis. A sandwich
immunoassay was used for measuring ﬁbulin-1 levels.[14,15] N-
terminal pro-B-type natriuretic peptide (NT-proBNP) and creatinine
were analyzed on a Modular Analytics P (Roche Diagnostics).
2.4. Clinical examination and follow-up
All patients underwent coronary angiography and a thorough
clinical examination prior to AVR. Operative risk was estimated using
the EuroScore [16]. By September 2012, outcome data was collected
from the Danish Central Population Registry (survival status) and
from discharge notes available in the Danish National Patient Registry.
In case of ambiguous information, local hospitals were contacted and
the patient's medical records were reviewed.Table 3
Echocardiographic characteristics of patients with new-onset atrial ﬁbrillation (NOAF).
NOAF
n = 23
No NOAF
n = 83
Aortic valve area (cm2) 0.81 ± 0.25 0.83 ± 0.28 0.80
Aortic valve area index (cm2/m2) 0.50 ± 0.19 0.46 ± 0.18 0.44
Aortic velocity (m/s) 4.1 ± 0.8 3.9 ± 0.8 0.46
Aortic valve mean gradient (mmHg) 41 ± 16 36 ± 17 0.18
Valvulo-arterial impedance (ml/mmHg) 4.8 ± 1.6 4.8 ± 1.5 0.97
Ejection fraction (%) 55 ± 8 54 ± 8 0.59
Left ventricular end-diastolic volume (ml) 111 ± 37 109 ± 32 0.85
Left ventricular mass index (g/m2) 138 ± 51 126 ± 35 0.17
Relative wall thickness 0.59 ± 0.16 0.59 ± 0.15 0.98
Left atrial volume index (ml/m2) 55 ± 21 44 ± 15 0.008
E-velocity (m/s) 0.82 ± 0.22 0.76 ± 0.21 0.24
A-velocity (m/s) 0.96 ± 0.27 0.91 ± 0.27 0.43
Deceleration time (ms) 196 ± 63 204 ± 55 0.52
Diastolic grade 0/7/9/6 5/32/40/5 0.03
Restrictive ﬁlling 6 (26) 5 (6) 0.005
e′ (cm/s) 5.5 ± 1.2 5.1 ± 1.4 0.15
s′ (cm/s) 5.7 ± 1.3 5.9 ± 1.3 0.64
E/e′ 17.4 ± 6.0 14.3 ± 4.8 0.02
Global longitudinal strain (%) −15.8 ± 4.1 −16.0 ± 3.4 0.78
Systolic left ventricular Strain rate (s−1) −0.86 ± 0.19 −0.85 ± 0.18 0.92
Mitral regurgitation grade 0/1/2 13/7/1 67/8/3 0.03
Candesartan 10 (43) 43 (52) 0.48
Abbreviations: NYHA New York Heart Association; CABG coronary aortic bypass graft; LV
Left ventricular; LVMi Left ventricular mass index; LA Left atrial.The primary endpoint of this study was new-onset atrial ﬁbrillation
deﬁned as (1) a hospitalization due to AF or (2) an episode of docu-
mented AF during a follow-up visit or on Holter monitoring. End points
were assessed by one of the investigators whowas blinded for all echo-
cardiographic measurements.
2.5. Statistics
Data are presented as mean ± standard deviation or number
and percentages. Differences between groups were tested by Student's
t-test; categorical variables were tested by Fisher's exact test. Due to a
non-Gaussian distribution, NT-proBNP was logarithm transformed. AF
and mortality rates were calculated using the product limit method
and plotted according to the Kaplan Meier method; rates were com-
pared using the log-rank test. Further estimation of risk was performed
using Cox proportional hazard models. The assumptions (proportional
hazard assumption, linearity of continuous variables and lack of interac-
tion) were tested and found valid. A p value b0.05 was considered
signiﬁcant. STATA/SE 9.0 (StataCorp LP, Texas, USA) software was
used for statistical analysis.
3. Results
A total of 125 patients were included, of which 19 had a history of AF
prior to surgery (Table 1).
3.1. Atrial ﬁbrillation prior to aortic valve replacement
These patients had similar comorbidity, gender distribution and
functional capacity as those without prior AF, although there was a
trend toward increased age, and higher EuroScore. Despite similar LV
ejection fraction, longitudinal systolic function was reduced in patients
with prior AF. Additionally, the presence of a restrictive LVﬁlling pattern
was more common in patients with prior AF. NT-proBNP was elevated
and LA volume increased. Despite higher transmitral E-wave velocities
among patients with prior AF, e′-velocities were also increased leading
to similar E/e′ values in both groups. Moreover, ﬁbulin-1 levels were
increased in patients with prior AF (104 ± 34 vs. 86 ± 32 μg/ml, p =
0.02).
3.2. New-onset atrial ﬁbrillation after aortic valve replacement
The mean follow- up duration for the total cohort was 4.6 ±
1.9 years (median 5.0 years). Survival status was available for all
patients. Of the 106 patients with no history of AF prior to AVR, 23
developed new-onset AF during follow-up (Table 2). In ﬁve patients,
asymptomatic AF was detected during clinical examination, 3 hadp=0.03
Fig. 1. Association of preoperative diastolic function with development of new-onset AF.
Fig. 2. Survival from atrial ﬁbrillation as a function restrictive ﬁlling pattern.
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hospitalized due to AF.
Patients developing new-onset AF had higher systolic blood pres-
sure prior to AVR, increased NT-proBNP levels and had more often
short episodes of SVT on Holter monitoring 3 month after AVR.
Restrictive LV ﬁlling pattern was more common among patients
developing new-onset AF (Table 3, Figs. 1 and 2), who also had more
advanced stages of diastolic dysfunction, although both longitudinalFig. 3. Atrial ﬁbrillation survival as a function of LA volume index (Panel A); E/e′ (Panel B); Numand circumferential systolic function was similar between groups. The
occurrence of mild or moderate mitral regurgitation was associated
with increased risk of new-onset AF, as was LA dilatation, presence of
increased ﬁlling pressures or N3 episodes of SVT (Table 3, Fig. 3). In
a univariable Cox regression analysis LAVi, restrictive ﬁlling pattern,
NT-proBNP, E/e′, systolic blood pressure and number of SVT episodes
were associated with the development of new-onset AF. When
correcting for age and LAVi, a restrictive ﬁlling pattern, systolic blood
pressure, and the number of SVT episodes remained associated with
new-onset AF (Table 4).
3.3. Clinical outcome
Overall, there were 38 deaths, six of them in patients with AF prior
to surgery. Eleven deaths were due to a non-cardiac cause (7= cancer,
3 = infectious disease, 1 = subarachnoid hemorrhage), whereas 27
patients had a cardiac cause of death (n = 16 sudden cardiac death,
n= 7 postoperative death, n= 3 congestive heart failure, n= 1 aortic
aneurysm). Forty-ﬁve patientsmet the secondary composite endpoint
(n = 27 cardiac death, n = 18 congestive heart failure). Overall and
cardiac mortality was similar irrespective of the occurrence of preop-
erative AF (5-year overall-survival 79% in patients with prior AF, vs.
75% in patients with no prior AF) (Fig. 4).
4. Discussion
The main ﬁnding in our study is that restrictive LV ﬁlling pattern,
increased LV ﬁlling pressures, and LA dilatation are associated withber of short SVT episodes on Holter (Panel C); Presence of mitral regurgitation (Panel D).
Table 4
Factors associated with development of new-onset AF.
Univariable Multivariablea
HR (95% CI) P HR p
Age 1.05 (0.99–1.11) 0.09
Left ventricular mass index (g/m) 1.01 (1.00–1.02) 0.11
Left atrial volume index (ml/m2) 1.03 (1.01–1.05) 0.006
Restrictive ﬁlling 3.5 (1.4–8.9) 0.008 3.01 (1.00–9.1) 0.05
NT-proBNP 1.47 (1.1–2.1) 0.02 1.23 (0.8–1.9) 0.32
E/e′ 1.11 (1.03–1.19) 0.003 1.07 (0.97–1.18) 0.17
Number of supraventricular tachycardia episodes in the 24 h Holter (3 month) 1.24 (1.1–1.4) 0.001 1.21 (1.06–1.38) 0.006
Preoperative systolic blood pressure 1.02 (1.00–1.04) 0.04 1.03 (1.00–1.10) 0.01
a 5 separate models adjusted for age and left atrial volume index.
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ment of new-onset AF after AVR in patients with severe AS. Indicating
that factors associated with LA pressure overload predicts new-onset
AF.
Moreover, we demonstrated that the presence of short runs of SVT
by Holter monitoring 3 months after AVR was associated with the
development of new-onset AF.
Various epidemiologic studies have shown that LVhypertrophy is as-
sociatedwith the risk of AF [4–6], although themechanism has not been
clearly established. In a recent study Amat-Santos and colleagues found
that LA size was the only echocardiographic predictor of new-onset AF
in patients with severe AS undergoing transcatheter aortic valve inter-
vention [17]. In addition, a retrospective analysis from the SEAS trial
demonstrated that LA size predicted new-onset AF in asymptomatic
AS patients [18]. We found a similar association between LA size and
AF in our study population, but beyond these ﬁndings we could also
demonstrate that patientswith AF had altered LV function and increased
ﬁlling pressures. In AS, both LV pressure overload and LV hypertrophy
might compromise coronary ﬂow reserve leading to subendocardial is-
chemia, which might result in reduced LV function. Thus, LV hypertro-
phy might lead to reduced LV function and increased ﬁlling pressures
resulting in LA dilatation and AF. Furthermore, the presence of increased
ﬁlling pressures and LAdilatationmight reﬂect alterations inmyocardial
compliance, as a restrictive ﬁlling pattern was more frequent among
patients with known AF and patients developing new-onset AF. Beyond
LV hypertrophy development of ﬁbrosis plays a role in myocardial
remodeling in AS. Although we can only speculate on the degree of
myocardial ﬁbrosis, we have recently shown that ﬁbulin-1 levels were
elevated in patients with known AF undergoing cardiac surgery com-
pared to patients with sinus rhythm [19]. Additionally, we have demon-
strated that ﬁbulin-1 levels correlatedwith echocardiographic indices ofFig. 4. Overall survival (Panel A) and survival from cardiovascular death (Pmyocardial stiffness and increased ﬁlling pressures suggesting that
ﬁbulin-1 might be a marker of myocardial ﬁbrosis. Further studies are
warranted to determine the signiﬁcance of ﬁbulin-1 in the setting of AF.
The association between LV remodeling and AF in this post-hoc
analysis of patients with severe AS might be explained by the ﬁndings
that treatment with candesartan led to increased LV reverse remodel-
ing, reducing LV hypertrophy and LA size [7], and thus preventing
development of AF 12 month after AVR [20]. Hence, treatment with
candesartan is likely to reduce the AF risk in patients with severe symp-
tomatic AS due to improvement of LV remodeling anddiastolic function.
During recent years, similar results from retrospective analyses have
been published in patients with LV dysfunction or hypertension
[21–24]. No large prospective randomized controlled trial, however,
has been able to conﬁrm these beneﬁcial effects of ACE-inhibitors or an-
giotensin receptor blockers to date, especially in patients with minimal
or no structural heart disease [25,26].
Another interesting ﬁnding of this study was the association
between short SVT episodes and development of AF among patients
with severe AS, which is in line with other reports from the literature.
Binici and colleagues found that more than thirty supraventricular
ectopic complexes per hour or short runs of SVT were associated with
a nearly three-fold risk of developing AF in an apparently healthy
population [27]. In patients with acute ischemic stroke, Wallmann
et al. found a six-fold increased risk of AF in those who had frequent
atrial premature beats [28].
4.1. Study limitations
Our sample size is relatively small, with few events, which make
our models unstable with a potential risk of overﬁtting the models.
The present study should be considered as hypothesis generating andanel B) as a function of the presence of preoperative atrial ﬁbrillation.
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by echocardiography, and no histologic examinations were performed;
thus, we can only speculate on the degree of myocardial and valvular
pathologies. No direct hemodynamic measurements of LV end-diastolic
or LA pressure were performed. However, E/e′ is accepted as a well-
validated surrogate of LV ﬁlling pressures in a wide range of patients
with cardiac disease including AS [11].
5. Conclusion
The present study demonstrates that the presence of preoperative
AF and development of new-onset AF after AVR are associated with
restrictive ﬁlling pattern, systolic blood pressure, increased LV ﬁlling
pressures, and LA dilatation in patients with severe AS.
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